New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Program Description

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive condition caused by the misfolding of the transthyretin (TTR) protein, which aggregates into amyloid fibrils that deposit in tissues and organs, such as the heart, impairing their function and structural integrity. Although often underdiagnosed due to nonspecific symptoms and overlap with other conditions, ATTR-CM has become more manageable with the growing number of FDA-approved disease-modifying therapies (DMTs). Managed care pharmacists play a critical role in navigating the expanding therapeutic landscape by supporting the development of clinical guidelines to facilitate evidence-based treatment selection, evaluate cost-effectiveness, ensure timely patient access, and make formulary decisions aligned with current recommendations. This session will provide an in-depth review of diagnostic strategies, current and emerging therapies, and clinical guidelines in ATTR-CM to help pharmacists make informed treatment and management decisions. With a greater understanding of diagnostic tools, available therapies, and current clinical guidance, managed care professionals and pharmacists will be better equipped to support timely, appropriate therapy selection and improve patients’ overall quality of life.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM) focusing on aspects such as patient quality of life, frequency of misdiagnosis, and the extent of health care resource use.
• Investigate current and emerging disease-modifying therapies for ATTR-CM by reviewing clinical guidelines, mechanisms of action, dosing strategies, administration considerations, and safety profiles
• Determine strategies to address the burden of high health care utilization in ATTR-CM by enhancing multidisciplinary care coordination and improving patient access to appropriate therapies within managed care settings

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-366-H01-P. The activity is available for CE credit through November 7, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Dejan Landup, PharmD, HF-Cert, has the following relevant financial relationships with ineligible companies to disclose: Regional advisory board: Alnylam, BridgeBio.

Jessin Joseph, PharmD, MBA, has the following relevant financial relationship with an ineligible company to disclose: employee of a PBM: vice president of Pharmacy Benefit Administration working primarily in sales and internal operations.

Drake Reiter, PharmD, RPh, has the following relevant financial relationship with an ineligible company to disclose: SUN Pharma (via COEUS).

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms